Skip to main content
Clinical Trials/NCT00402675
NCT00402675
Completed
Phase 4

Leipzig Immediate Versus Early and Late PercutaneouS Coronary Intervention triAl in NSTEMI - LIPSIA-NSTEMI TRIAL

University of Leipzig5 sites in 1 country600 target enrollmentJuly 2006

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
University of Leipzig
Enrollment
600
Locations
5
Primary Endpoint
peak creatine kinase- MB level
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

In non-ST-elevation the optimal time of percutaneous coronary intervention (PCI) is unclear.

Some studies showed benefit of very early PCI, some others early PCI between 12-48 hours and others even showed a benefit of a selective invasive approach only in case of recurrence of symptoms or a positive stress test.

The optimal timing of intervention is still matter of debate as a result of a randomized clinical trial.

Detailed Description

In this randomized, controlled, open-label clinical trial we compare a very early cardiac catheterization (\< 2,5 hours after randomization) similar to ST-elevation myocardial infarction treatment, versus an early invasive approach (within 2-48 hours after randomization) versus a selective invasive approach in patients with non-ST-elevation myocardial infarction. All patients are treated with heparin, ASA, Clopidogrel loading dose (600 mg) with subsequent 75 mg/d and tirofiban for 24 hours.

Registry
clinicaltrials.gov
Start Date
July 2006
End Date
January 2010
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University of Leipzig

Eligibility Criteria

Inclusion Criteria

  • Clinical symptoms:
  • Instable angina pectoris:
  • Angina at rest \< 24 hours
  • new onset worsening angina within the last weeks with angina at very low threshold \< 24 h
  • Troponin T:
  • Troponin T-elevation ≥ 0,03 μg/l
  • Informed consent

Exclusion Criteria

  • Age \< 18 years
  • Age \> 90 years
  • Hemodynamic instability
  • Cardiogenic shock
  • Warfarin therapy
  • Contraindications for GpIIb/IIIa-inhibitors
  • life expectancy \< 6 months
  • known high bleeding risk
  • Other reasons for Troponin-elevation: Myocarditis, secondary after hypertensive crisis, cardiac decompensation
  • No informed consent

Outcomes

Primary Outcomes

peak creatine kinase- MB level

Time Frame: 5 days

Secondary Outcomes

  • Major bleeding complications (GUSTO definition)(30 days)
  • Composite: death, re-myocardial infarction, recurrent unstable angina(6 months)

Study Sites (5)

Loading locations...

Similar Trials